Insilico Medicine H1 2026: Revenue US$106.3M, Up 287%; First Profitable Half-Year

Generative-AI drug-discovery company Insilico Medicine (HKEX: 3696) reported H1 2026 results: total revenue US$106.3M (+287.2% YoY), gross margin 90.3%, net profit US$35.54M, adjusted net profit US$51.23M, operating cash flow positive; YTD BD contract value ~US$7.3B with 9 PCC nominations and 8 clinical advancements.

On August 26, 2026, generative-AI-driven clinical-stage drug-discovery company Insilico Medicine (HKEX: 3696) released its 2026 interim results. H1 total revenue reached US$106.3M, up 287.2% year-over-year; gross margin was 90.3%; net profit was US$35.54M and adjusted net profit US$51.23M, marking its first profitable half-year, with operating cash flow turning positive. As of June 30, cash and investment portfolio totaled ~US$584.8M.

By segment, drug-discovery and pipeline revenue was US$103.1M (>300% YoY) and software-solutions revenue ~US$2.70M. Year-to-date, total contract value of out-licensing and R&D partnerships reached ~US$7.3B, validating its 'AI platform + proprietary pipeline + BD monetization' commercialization path.

Global BD partnerships landed densely: in the US/EU, a US$888M oncology collaboration with Servier (US$32M upfront) in January and a US$2.75B license & R&D deal with Eli Lilly (US$115M upfront) in March; in Greater China, US$66M with Hygtia and HK$931M with Qilu in January, a deepened tie with CMS (over RMB 1.2B) in Feb/June, and US$94.75M with Tenacia for CNS in March; in APAC, US$2.5B with SK Biopharmaceuticals in June and ~US$600M with Takeda (≈US$60M initiation) in July.

AI agents and infrastructure kept iterating: Science MMAI Gym (Jan), PandaClaw (Mar), open-source autonomous-lab OS LabClaw (May), and DDD Benchmarks as BaaS (Jul), plus partnerships with Google Cloud and Tencent Health. On the pipeline, 9 PCC nominations and 8 clinical advancements were advanced in H1 — Rentosertib Phase III in China with its inhaler gaining CDE IND; ISM8969/HT-001 securing FDA IND and first-in-human dosing; ISM6331 granted FDA Fast Track, among others.

On capital markets and recognition, 13 brokers now cover the stock; it was included in Stock Connect and the Hang Seng Composite Index on March 9, later entering CSI, FTSE and MSCI Small Cap indices; it earned a Galien Best Startup nomination and ranked #3 on Fast Company's 2026 Most Innovative Biotech list. Insilico demonstrates that generative-AI-driven drug discovery has reached a verifiable commercial closed loop.